The NIH is to fund research evaluating the use of chromium picolinate in people with type 2 diabetes. The findings could significantly boost chromium specialist Nutrition 21, whose Chromax brand is being used in the trial.
The National Institutes of Health grant to be used by Dr William Cefalu, at the Pennington Biomedical Research Center of Louisiana State University, is expected to make considerably add to the existing body of clinical evidence demonstrating the role of chromium picolinate in the management of diabetes.
"The trial will use 'gold standard' techniques to evaluate carbohydrate metabolism in human subjects with type 2 diabetes and will also use techniques to evaluate the specific mechanism by which it may work," said Dr Cefalu.
There are currently 13 published human clinical studies demonstrating significant efficacy with chromium picolinate supplementation in diabetes and metabolic syndrome.
Gail Montgomery, president and CEO of Nutrition 21, said: "The significant investment by the NIH in chromium picolinate research complements, and is expected to further validate, our own aggressive research and development program."
She added: "In keeping with Nutrition 21's business strategy, we expect government participation to help facilitate our near-term objective of securing Food and Drug Administration (FDA) approved health claims for our products."
This should accelerate the firm's ultimate goal of having its proprietary chromium technologies incorporated in standard health plan treatment protocols for people with diabetes, continued Montgomery.
Nutrition 21 currently holds 22 patents for chromium compounds and their uses.